当前位置: 首页 » 论文下载 » 医药、卫生 »
米非司酮配伍米索前列醇抗早早孕的临床探讨
 

文档类型:Word文档

文件大小:0.07M

下载次数:0

更新日期:2013-12-19 09:26

浏览次数:898

下载

 
详细介绍
 

米非司酮配伍米索前列醇抗早早孕的临床探讨

 

摘要 目的  探讨米非司酮配伍米索前列醇用于抗早早孕的疗效及其可行性。方法 将自愿药物流产的妇女 222例分为 2组。观察组为停经< 40天,早孕试验阳性 ,阴道B超检查宫内未见孕囊者 112 对照组为孕周≤ 4 9 ,确诊为宫内妊娠110例。观察两组给药后流产情况、阴道流血时间、流血量、HCG转阴、及药物不良反应等情况。结果 观察组阴道排出物见绒毛及蜕膜组织者 98 ,完全流[1]产率 97.32% ,子宫出血时间≤ 7 9 9 (90.08 % ) ,出血量月经量 96 (88.07% ) ,两组流产率无显著差异(P 0 .0 5 ),两组阴道出血时间、出血量有显著差异(P0.05)。结论 米非司酮配伍米索前列醇抗早早孕效果好 ,是一种安全、有效的方法,在严格掌握适应症的情况下值得推广使用。

关键词   米非司酮   米索前列醇  抗早早孕

 

Clinical study on combination of mifepristone with misoprostol on termination of early pregnancy

[Abstract] Objective To study the effects and feasibility on combination of mifepristone with misoprostol on termination of early pregnancy. Methods To divide 222 cases of pregnant women voluntarily to take abortion drugs into two groups. The treatment group with gestation period less than 40 days, positive early pregnancy test, B-scan vaginal no intrauterine pregnancy sac(n=112), and the control group with a length of gestational age less than 49 days, diagnosed of intrauterine pregnancy(n=110). Monitor the abortions after drugs, vaginal bleeding period, bleeding volumn, HCG turning to be negative, adverse drug reactions, etc. of these two groups. Results The observe group had 98 cases of villi and decidual visible in vaginal discharges, the rate of complete abortion 97.32%, and 99 cases of bleeding period less than 7 days(90.08%), 96 cases of bleeding volumn less than menstruation volumn(88.07%), There was no significant difference between the two groups in abortion rate(P>0.05), while there were noticeable differences in bleeding period and volumn(P<0.05). Conclusion Combination of mifepristone with misoprostol can work effectively on termination of early pregnancy. It is a safe and effective method which deserves popularizing in circumstances that indications are strictly controlled.

[Key words] mifepristone; misoprostol; termination of early pregnancy.




 

 
 


您还没登录,登录后查看详情

免费注册会员以后,您可以享受以下权利

 


 
评论详情
 
0条 [查看全部]  相关评论
 类浏览
 
 
 
 
 
 
 

本站产品最终解释权归QIKANN.COM

 
 
展开